{"id":531070,"date":"2021-02-20T18:58:02","date_gmt":"2021-02-20T18:58:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531070"},"modified":"2021-02-20T18:58:02","modified_gmt":"2021-02-20T18:58:02","slug":"complex-regional-pain-syndrome-crps-market-size-share-epidemiology-market-research-and-forecast-report-2030-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/complex-regional-pain-syndrome-crps-market-size-share-epidemiology-market-research-and-forecast-report-2030-by-delveinsight_531070.html","title":{"rendered":"Complex Regional Pain Syndrome (CRPS) Market Size, Share, Epidemiology, Market Research and Forecast Report 2030 by DelveInsight"},"content":{"rendered":"
\"Complex<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Complex Regional Pain Syndrome (CRPS) – Market Insights, Epidemiology, and Market Forecast\u20142030\u2019 report deliver an in-depth understanding of the CRPS, historical and forecasted epidemiology as well as the CRPS market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.\n<\/div>\n

DelveInsight launched a new report on Complex Regional Pain Syndrome (CRPS) Market Insights, Epidemiology and Market Forecast 2030<\/a><\/strong>.<\/p>\n

DelveInsight’s ‘Complex Regional Pain Syndrome (CRPS) Market 2030<\/strong><\/a>’ report delivers an in-depth understanding of the CRPS, historical and forecasted epidemiology as well as the CRPS market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.<\/p>\n

\"\"<\/p>\n

Complex regional pain syndrome (CRPS) is one of the most challenging chronic pain condition that is characterized by progressively worsening spontaneous regional pain without dermatomal distribution. The pain experienced is out of proportion in time and severity to the inciting event and accompanied by symptoms that vary in severity including skin changes, autonomic dysfunction, abnormal sensory and motor changes, and trophic changes.<\/p>\n

CRPS may develop after major trauma, surgery, or minor injury, and progresses with a variable course that ranges from self-limiting, mild symptomatology to chronic disease. In many cases, disease progression is debilitating and severely limits patients’ quality of life, creating a tremendous burden on patients and their families. Over time, CRPS has been defined and redefined. CRPS develops after an inciting noxious stimulus to an affected limb. There is little agreement with regards to the etiology, symptoms, clinical presentation, diagnosis, or treatment of CRPS.<\/p>\n

Request for a detailed sample copy of the report: https:\/\/www.delveinsight.com\/sample-request\/complex-regional-pain-syndrome-market<\/a>
<\/a><\/strong><\/p>\n

Complex Regional Pain Syndrome Epidemiology Insights:<\/strong><\/p>\n

1. In the United States, the total number of prevalent cases of CRPS was 219,317 cases in the year 2017 which are expected to grow during the study period, i.e., 2017–2030.<\/p>\n

2. In the 7MM, the total gender-specific diagnosed prevalent cases of CRPS were 47,699 for males and 102,987 for females in the year 2017.<\/p>\n

Complex Regional Pain Syndrome (CRPS) Therapy Assessment<\/strong><\/p>\n

1. Soticlestat (TAK-935\/OV935): Ovid Therapeutics\/Takeda<\/p>\n

2. BHV-5000: AstraZeneca\/Biohaven Pharmaceutical<\/p>\n

Click here and get access to free sample pages of the report.<\/strong><\/a><\/p>\n

Table of contents<\/strong><\/p>\n

1 Key Insight
2 Executive Summary of Complex Regional Pain Syndrome (CRPS)
3 Complex Regional Pain Syndrome (CRPS) Market Overview at a Glance
4 Disease Background and Overview: Complex Regional Pain Syndrome (CRPS)
5 Case Reports
6 Complex Regional Pain Syndrome (CRPS) Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Complex Regional Pain Syndrome (CRPS) Treatment and Medical Practices
11 Unmet needs
12 Complex Regional Pain Syndrome (CRPS) Marketed Drugs
13 Complex Regional Pain Syndrome (CRPS) Emerging Drugs
14 Complex Regional Pain Syndrome (CRPS) 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Complex Regional Pain Syndrome (CRPS) Market Drivers
19 Complex Regional Pain Syndrome (CRPS) Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight<\/p>\n

About DelveInsight<\/strong><\/p>\n

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight\u2019s \u2018Complex Regional Pain Syndrome (CRPS) – Market Insights, Epidemiology, and Market Forecast\u20142030\u2019 report deliver an in-depth understanding of the CRPS, historical and forecasted epidemiology as well as the CRPS market trends in the United States, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-531070","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=531070"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531070\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=531070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=531070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=531070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}